BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34
BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ: KZIA ) with a Buy rating and announces Price Target of $34.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.